{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:17:52Z","timestamp":1791980272826,"version":"4.4.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"imwell Charitable Trust"},{"name":"dolph and Klara Brettler Center of the Hebrew University's School of Pharmacy"},{"name":"srael Science Foundation"},{"name":"INECO-FEDER (Spain-UE);"},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.phrs.2020.104682","type":"journal-article","created":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T11:53:52Z","timestamp":1580903632000},"page":"104682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Activation of Siglec-7 results in inhibition of in vitro and in vivo growth of human mast cell leukemia cells"],"prefix":"10.1016","volume":"158","author":[{"given":"Nadine","family":"Landolina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Zaffran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dubravka","family":"Smiljkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Serrano-Candelas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Schmiedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheli","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Arock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Pikarsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Mandelboim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Levi-Schaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.phrs.2020.104682_bib0005","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1172\/JCI0214843","article-title":"ITAMs versus ITIMs: striking a balance during cell regulation","volume":"109","author":"Billadeau","year":"2002","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.phrs.2020.104682_bib0010","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1084\/jem.184.3.839","article-title":"Signaling capacity of the T cell antigen receptor is negatively regulated by the PTP1C tyrosine phosphatase","volume":"184","author":"Pani","year":"1996","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.phrs.2020.104682_bib0015","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.4049\/jimmunol.0901972","article-title":"SHP-1 deficient mast cells are hyperresponsive to stimulation and critical in initiating allergic inflammation in the lung","volume":"184","author":"Zhang","year":"2010","journal-title":"J. Immunol."},{"issue":"41","key":"10.1016\/j.phrs.2020.104682_bib0020","doi-asserted-by":"crossref","first-page":"29549","DOI":"10.1074\/jbc.274.41.29549","article-title":"Regulation of acidification and apoptosis by SHP-1 and Bcl-2","volume":"274","author":"Thangaraju","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"17","key":"10.1016\/j.phrs.2020.104682_bib0025","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1111\/bph.13929","article-title":"WMJ-8-B, a novel hydroxamate derivative, induces MDA-MB-231 breast cancer cell death via the SHP-1-STAT3-survivin cascade","volume":"174","author":"Chuang","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2020.104682_bib0030","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/2024648","article-title":"Dovitinib triggers apoptosis and autophagic cell death by targeting SHP-1\/p-STAT3 signaling in human breast cancers","author":"Chiu","year":"2019","journal-title":"J. Oncol."},{"issue":"4","key":"10.1016\/j.phrs.2020.104682_bib0035","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nri2056","article-title":"Siglecs and their roles in the immune system","volume":"7","author":"Crocker","year":"2007","journal-title":"Nat. Rev. Immunol."},{"issue":"48","key":"10.1016\/j.phrs.2020.104682_bib0040","doi-asserted-by":"crossref","first-page":"34089","DOI":"10.1074\/jbc.274.48.34089","article-title":"Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes","volume":"274","author":"Nicoll","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2020.104682_bib0045","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/imr.12526","article-title":"Viewing Siglecs through the lens of tumor immunology","volume":"276","author":"Fraschilla","year":"2017","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.phrs.2020.104682_bib0050","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jaci.2014.03.031","article-title":"Siglec-7 is an inhibitory receptor on human mast cells and basophils","volume":"134","author":"Mizrahi","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"issue":"5","key":"10.1016\/j.phrs.2020.104682_bib0055","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1182\/blood-2005-07-2926","article-title":"The inhibitory receptor IRp60 (CD300a) suppresses the effects of IL-5, GM-CSF, and eotaxin on human peripheral blood eosinophils","volume":"107","author":"Munitz","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.phrs.2020.104682_bib0060","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/glycob\/cwq116","article-title":"Ganglioside DSGb5, preferred ligand for Siglec-7, inhibits NK cell cytotoxicity against renal cell carcinoma cells","volume":"20","author":"Kawasaki","year":"2010","journal-title":"Glycobiology"},{"issue":"7","key":"10.1016\/j.phrs.2020.104682_bib0065","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1111\/all.13730","article-title":"Siglec-7 on peripheral blood eosinophils: surface expression and function","volume":"74","author":"Legrand","year":"2019","journal-title":"Allergy"},{"issue":"10","key":"10.1016\/j.phrs.2020.104682_bib0070","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1073\/pnas.091097198","article-title":"Surface expression and function of p75\/AIRM-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cells","volume":"98","author":"Vitale","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"26","key":"10.1016\/j.phrs.2020.104682_bib0075","doi-asserted-by":"crossref","first-page":"15091","DOI":"10.1073\/pnas.96.26.15091","article-title":"Engagement of p75\/AIRM1 or CD33 inhibits the proliferation of normal or leukemic myeloid cells","volume":"96","author":"Vitale","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.phrs.2020.104682_bib0080","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk. Res."},{"issue":"11","key":"10.1016\/j.phrs.2020.104682_bib0085","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2020.104682_bib0090","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1146\/annurev-pathol-052016-100312","article-title":"Pathogenesis and pathology of mastocytosis","volume":"12","author":"Metcalfe","year":"2017","journal-title":"Annu. Rev. Pathol."},{"issue":"6","key":"10.1016\/j.phrs.2020.104682_bib0095","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-16-2234","article-title":"Advances in the classification and treatment of mastocytosis: current status and outlook toward the future","volume":"77","author":"Valent","year":"2017","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.phrs.2020.104682_bib0100","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jaci.2017.06.007","article-title":"Mast cell activation syndromes","volume":"140","author":"Akin","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"issue":"23","key":"10.1016\/j.phrs.2020.104682_bib0105","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.phrs.2020.104682_bib0110","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.iac.2018.04.005","article-title":"Kit mutations: new insights and diagnostic value","volume":"38","author":"Falchi","year":"2018","journal-title":"Immunol. Allergy Clin. North Am."},{"issue":"6","key":"10.1016\/j.phrs.2020.104682_bib0115","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia."},{"issue":"4","key":"10.1016\/j.phrs.2020.104682_bib0120","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1172\/JCI116761","article-title":"Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product","volume":"92","author":"Furitsu","year":"1993","journal-title":"J. Clin. Invest."},{"issue":"8","key":"10.1016\/j.phrs.2020.104682_bib0125","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/blood.V87.8.3117.bloodjournal8783117","article-title":"A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells","volume":"87","author":"Piao","year":"1996","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.phrs.2020.104682_bib0130","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1073\/pnas.96.4.1609","article-title":"Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis","volume":"96","author":"Longley","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.phrs.2020.104682_bib0135","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.2353\/ajpath.2009.080953","article-title":"Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V","volume":"175","author":"Baumgartner","year":"2009","journal-title":"Am. J. Pathol."},{"issue":"6","key":"10.1016\/j.phrs.2020.104682_bib0140","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2007-09-115477","article-title":"Oncogenic Kit controls neoplastic mast cell growth through a Stat5\/PI3-kinase signaling cascade","volume":"112","author":"Harir","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.phrs.2020.104682_bib0145","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood-2005-06-2433","article-title":"Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells","volume":"108","author":"Gabillot-Carre","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.phrs.2020.104682_bib0150","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1365-2567.2003.01559.x","article-title":"Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene","volume":"108","author":"Sundstrom","year":"2003","journal-title":"Immunology"},{"issue":"8","key":"10.1016\/j.phrs.2020.104682_bib0155","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0145-2126(02)00343-0","article-title":"Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma\/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI","volume":"27","author":"Kirshenbaum","year":"2003","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.phrs.2020.104682_bib0160","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood-2013-10-534685","article-title":"A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection","volume":"124","author":"Saleh","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.phrs.2020.104682_bib0165","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1093\/annonc\/mdx290","article-title":"Midostaurin: a magic bullet that blocks mast cell expansion and activation","volume":"28","author":"Valent","year":"2017","journal-title":"Ann. Oncol."},{"issue":"26","key":"10.1016\/j.phrs.2020.104682_bib0170","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.phrs.2020.104682_bib0175","first-page":"1500","article-title":"Systemic mastocytosis, version 2.2019, NCCN clinical practice guidelines in oncology","volume":"16","author":"Gotlib","year":"2018","journal-title":"J. Compr. Canc. Netw."},{"issue":"3","key":"10.1016\/j.phrs.2020.104682_bib0180","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.iac.2018.04.007","article-title":"Tyrosine kinase inhibition in mastocytosis: KIT and beyond KIT","volume":"38","author":"Bibi","year":"2018","journal-title":"Immunol. Allergy Clin. North Am."},{"issue":"4","key":"10.1016\/j.phrs.2020.104682_bib0185","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0145-2126(88)90050-1","article-title":"Establishment of an immature mast cell line from a patient with mast cell leukemia","volume":"12","author":"Butterfield","year":"1988","journal-title":"Leuk. Res."},{"issue":"6","key":"10.1016\/j.phrs.2020.104682_bib0190","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1084\/jem.190.6.793","article-title":"Identification and molecular cloning of p75\/AIRM1, a novel member of the sialoadhesin family that functions as an inhibitory receptor in human natural killer cells","volume":"190","author":"Falco","year":"1999","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.phrs.2020.104682_bib0195","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1128\/MCB.18.4.2089","article-title":"SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain","volume":"18","author":"Kozlowski","year":"1998","journal-title":"Mol. Cell. Biol."},{"issue":"2","key":"10.1016\/j.phrs.2020.104682_bib0200","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nprot.2007.25","article-title":"Establishment of human tumor xenografts in immunodeficient mice","volume":"2","author":"Morton","year":"2007","journal-title":"Nat. Protoc."},{"issue":"7","key":"10.1016\/j.phrs.2020.104682_bib0205","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/glycob\/cwi048","article-title":"Characterization of inhibitory signaling motifs of the natural killer cell receptor Siglec-7: attenuated recruitment of phosphatases by the receptor is attributed to two amino acids in the motifs","volume":"15","author":"Yamaji","year":"2005","journal-title":"Glycobiology"},{"issue":"1","key":"10.1016\/j.phrs.2020.104682_bib0210","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1182\/asheducation-2018.1.127","article-title":"The new tool \u201cKIT\u201d in advanced systemic mastocytosis","author":"Shomali","year":"2018","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"issue":"5","key":"10.1016\/j.phrs.2020.104682_bib0215","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.4049\/jimmunol.177.5.3063","article-title":"CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo","volume":"177","author":"Haas","year":"2006","journal-title":"J. Immunol."},{"issue":"28","key":"10.1016\/j.phrs.2020.104682_bib0220","doi-asserted-by":"crossref","first-page":"43281","DOI":"10.18632\/oncotarget.9674","article-title":"Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia","volume":"7","author":"Laszlo","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2020.104682_bib0225","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1034\/j.1600-065X.2001.1810122.x","article-title":"p75\/AIRM1 and CD33, two sialoadhesin receptors that regulate the proliferation or the survival of normal and leukemic myeloid cells","volume":"181","author":"Mingari","year":"2001","journal-title":"Immunol. Rev."},{"issue":"9","key":"10.1016\/j.phrs.2020.104682_bib0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0045821","article-title":"Engagement of Siglec-7 receptor induces a pro-inflammatory response selectively in monocytes","volume":"7","author":"Varchetta","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.phrs.2020.104682_bib0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106239","article-title":"Role of Siglec-7 in apoptosis in human platelets","volume":"9","author":"Nguyen","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.phrs.2020.104682_bib0240","doi-asserted-by":"crossref","first-page":"7989","DOI":"10.4049\/jimmunol.175.12.7989","article-title":"The inhibitory receptor IRp60 (CD300a) is expressed and functional on human mast cells","volume":"175","author":"Bachelet","year":"2005","journal-title":"J. Immunol."},{"issue":"22","key":"10.1016\/j.phrs.2020.104682_bib0245","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2018-05-853291","article-title":"TET2 deficiency leads to stem cell factor dependent clonal expansion of dysfunctional erythroid progenitors","volume":"132","author":"Qu","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.phrs.2020.104682_bib0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206364","article-title":"Stem cell factor and NSC87877 combine to enhance c-Kit mediated proliferation of human megakaryoblastic cells","volume":"13","author":"Raghav","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2020.104682_bib0255","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.mrfmmm.2018.02.001","article-title":"A change in structural integrity of c-Kit mutant D816V causes constitutive signaling","volume":"808","author":"Raghav","year":"2018","journal-title":"Mutat. Res."},{"issue":"9","key":"10.1016\/j.phrs.2020.104682_bib0260","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.4049\/jimmunol.180.9.6064","article-title":"Suppression of normal and malignant kit signaling by a bispecific antibody linking kit with CD300a","volume":"180","author":"Bachelet","year":"2008","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.phrs.2020.104682_bib0265","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/glycob\/cwp195","article-title":"Siglec-7 mediates nonapoptotic cell death independently of its immunoreceptor tyrosine-based inhibitory motifs in monocytic cell line U937","volume":"20","author":"Mitsuki","year":"2010","journal-title":"Glycobiology"},{"issue":"7","key":"10.1016\/j.phrs.2020.104682_bib0270","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/eji.200636195","article-title":"You say ITAM and I say ITIM, let\u2019s call the whole thing off: the ambiguity of immunoreceptor signalling","volume":"36","author":"Barrow","year":"2006","journal-title":"Eur. J. Immunol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819325630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819325630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:19:18Z","timestamp":1760912358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661819325630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":54,"alternative-id":["S1043661819325630"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2020.104682","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activation of Siglec-7 results in inhibition of in vitro and in vivo growth of human mast cell leukemia cells","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2020.104682","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104682"}}